NAD+

NAD+ Regulatory Status

UKPWritten and published by UK Peptides2 min readUpdated 4 cited sources

The short answer

NAD+ holds no marketing authorisation as a medicine from the MHRA, EMA or FDA. Some precursors are sold as food supplements in some jurisdictions, which is a different regulatory category with different rules, and neither position permits therapeutic claims.

Key facts

MHRA medicine status
Not authorised
EMA medicine status
Not authorised
FDA drug status
Not approved
Precursors
Food supplement status in some jurisdictions
Supply basis here
Laboratory research only
Highest-risk framing
Ageing and longevity language

The position

No regulator has authorised NAD+ as a medicine. Some precursors (nicotinamide riboside in particular) have food supplement status in certain jurisdictions, which permits sale but not therapeutic claims. Those are separate frameworks, and neither one covers NAD+ supplied as laboratory research material.

Why the supplement route confuses things

Because a compound sold legally in a shop looks approved. It is not. Food supplement frameworks assess safety for consumption; they do not assess efficacy for any purpose and do not permit claims that a product treats or prevents anything. A precursor's supplement status says nothing about NAD+, and nothing about efficacy.

Research material referenced

NAD+ 500mg, third-party HPLC tested

Buy NAD+ · £49.99

The claims problem specific to this category

The ageing literature is the most claim-prone body of work on this site. Its vocabulary (decline, restoration, reversal, longevity) reads as therapeutic before any claim is deliberately made, and it maps onto something everyone experiences. That combination makes the boundary easier to cross here than anywhere else in the catalogue.

Where the line sits

Reportable: that tissue NAD+ declines with age, that Covarrubias 2020 identified senescent-cell CD38 activity as a driver, that randomised trials of precursors have measured biomarker and physiological endpoints. Not sayable: that NAD+ slows ageing, restores energy, extends lifespan or affects any condition in any person.

The enforcement context

The MHRA opened investigations into UK retailers making therapeutic claims about unregulated products in April 2026. The framework turns on the claim and intended use, not on the compound's chemistry. A non-peptide in a peptide catalogue is therefore regulated on the same basis as everything around it.

Frequently asked questions

Is NAD+ approved as a medicine?

No. It holds no marketing authorisation from the MHRA, EMA or FDA.

NR is sold in shops. Doesn't that mean it's approved?

No. Food supplement status assesses safety for consumption, not efficacy, and permits no therapeutic claims.

Why is this category particularly claim-prone?

The ageing literature's vocabulary reads as therapeutic before any claim is made, and it maps onto something universally experienced.

Continue researching

Related guides and reference material.

Primary sources & clinical trials

Published papers, trial registrations, regulator pages and company announcements. Links open the original.

UKP

Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).

Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.

Corrections log

More NAD+ articles

Research use only. The information above is provided for scientific and educational reference. Compounds referenced are not approved for human use and are supplied for in vitro research or reference-material purposes only. No efficacy, safety, or therapeutic claims are made.